|1.||Rock, Dan A: 2 articles (12/2015 - 10/2012)|
|2.||Goldmacher, Victor S: 2 articles (06/2015 - 07/2006)|
|3.||Wang, Lintao: 2 articles (06/2015 - 07/2006)|
|4.||Lopus, Manu: 2 articles (08/2011 - 10/2010)|
|5.||Widdison, Wayne: 2 articles (04/2011 - 10/2010)|
|6.||Wilhelm, Sharon: 2 articles (04/2011 - 10/2010)|
|7.||Chari, Ravi: 2 articles (04/2011 - 10/2010)|
|8.||Quon, Kim C: 1 article (12/2015)|
|9.||Patel, Sonal K: 1 article (12/2015)|
|10.||Gurgel, Jesse L: 1 article (12/2015)|
|1.||Breast Neoplasms (Breast Cancer)
04/01/1980 - "Maytansine is an experimental antitumor agent that has shown minimal efficacy against breast cancer with minimal myelosuppression in phase I trials. "
05/01/1981 - "Phase II study of maytansine in advanced breast cancer."
04/01/1980 - "Minimal single-agent activity of maytansine in refractory breast cancer: a Southwest Oncology Group study."
12/15/2015 - "Taken together, our results establish SLC46A3 as a direct transporter of maytansine-based catabolites from the lysosome to the cytoplasm, prompting further investigation of SLC46A3 as a predictive response marker in breast cancer specimens. "
01/01/2012 - "The potential of maytansine was found in the 1970s with clinical responses noted against breast cancer; however, substantial toxicity prohibited further development. "
03/01/2005 - "Metabolism studies of the anti-tumor agent maytansine and its analog ansamitocin P-3 using liquid chromatography/tandem mass spectrometry."
06/01/2015 - "The maytansinoid antibody-drug conjugates (ADCs) in clinical development for cancer therapy each contain a derivative of the microtubule-targeting agent, maytansine, covalently attached to the antibody via an engineered linker. "
01/01/2014 - "In conclusion, the maytansine-NPs offer a considerable potential formulation for FR-expressing tumor targeting biotherapy. "
10/01/2012 - "The in vitro characterization of the inhibition potential of four representative maytansinoid species observed upon hepatic and/or tumor in vivo processing of antibody-maytansine conjugates (AMCs) with cleavable and noncleavable linkers is reported. "
08/28/2011 - "DM1 is an antibody-conjugatable maytansinoid that was developed to overcome systemic toxicity associated with maytansine and to enhance tumor-specific delivery. "
|3.||Melanoma (Melanoma, Malignant)
03/01/1979 - "During the phase I study of maytansine at our institution, some activity was observed against breast carcinoma and melanoma. "
03/01/1979 - "Results of a phase II study of maytansine in patients with breast carcinoma and melanoma."
04/01/1980 - "Phase II study of maytansine and chlorozotocin in patients with disseminated malignant melanoma."
06/01/1983 - "Phase II study of maytansine in the treatment of advanced or recurrent adenocarcinoma of the ovary. "
06/01/1983 - "Maytansine thus appears inactive in the treatment of adenocarcinoma of the ovary at the dose and schedule tested."
06/01/1983 - "Twenty-nine patients with advanced or recurrent adenocarcinoma of the ovary no longer responsive to standard treatment measures were given maytansine 1.2 mg/m2 I.V. every 3 weeks. "
04/01/1985 - "Phase II trials of maytansine, low-dose chlorozotocin, and high-dose chlorozotocin as single agents against advanced measurable adenocarcinoma of the pancreas. "
09/15/1975 - "Initial studies on maytansine-induced metaphase arrest in L1210 murine leukemia cells."
01/01/1978 - "Stathmokinetic and therapeutic effects of maytansine in mice bearing P388 and L1210 leukemias."
04/01/1979 - "Bis(N-ethylidenevindesine) disulfide, the first example of a bridged bisvindesine and comparable to VDS in its antitumor profile, shows evidence of activity against a P388/VCR leukemia strain known to be resistant to maytansine as well as to vincristine."
03/01/1978 - "Flow microfluorometric analysis of P388 murine leukemia after administration of vincristine and maytansine in vivo."
08/01/2004 - "We examined the cytotoxic effect of maytanprine isolated from the methanol extract of Maytenus diversifolia on human leukemia K562 cells using a flow cytometer and compared its cytotoxicity with that of maytansine, a potent cytotoxic maytansinoid. "
|7.||Vinblastine (Vinblastine Sulfate)
|8.||Epidermal Growth Factor Receptor (EGF Receptor)
|1.||Drug Therapy (Chemotherapy)
|2.||Heterologous Transplantation (Xenotransplantation)